Design Therapeutics (NASDAQ:DSGN) outlined progress across three clinical-stage programs and discussed upcoming catalysts during an Oppenheimer healthcare conference presentation led by CEO Pratik Shah. The company is developing what it describes as “small molecule genetic medicines” designed to modulate expression of individual genes—either increasing or decreasing expression—to address the root cause of certain single-gene disorders. […]

Design Therapeutics (NASDAQ:DSGN) outlined progress across three clinical-stage programs and discussed upcoming catalysts during an Oppenheimer healthcare conference presentation led by CEO Pratik Shah. The company is developing what it describes as “small molecule genetic medicines” designed to modulate expression of individual genes—either increasing or decreasing expression—to address the root cause of certain single-gene disorders. […]